Dawnrays Pharmaceutical (Holdings) Full Year 2023 Earnings: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.15b (down 9.9% from FY 2022).
• Net income: CN¥326.0m (down 9.0% from FY 2022).
• Profit margin: 28% (in line with FY 2022).
• EPS: CN¥0.22 (down from CN¥0.24 in FY 2022).

2348 Post-Clinical Trial Products

• Pre-registration: 11.
• Approved (during full year): 8.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Finished Drugs segment contributing a total revenue of CN¥1.02b (89% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥147.0m (42% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥50.0m. Explore how 2348's revenue and expenses shape its earnings.

Dawnrays Pharmaceutical (Holdings)'s share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Dawnrays Pharmaceutical (Holdings) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.